MedImmune, Micromet cancer deal

Under a co-development deal, Micromet (Munich, Germany) granted MedImmune (MEDI) North American development rights to its MT103 bispecific T cell

Read the full 205 word article

How to gain access

Continue reading with a
two-week free trial.